Episurf Medical AB (STO:EPISB), a provider of minimally invasive and personalised treatment alternatives for people with painful joint injuries, announced on Friday that it has CE-marked a new knee joint visualisation tool, which will be released to the European market following a controlled launch process.
This tool, named Epioscopy, is a web-based application based on artificial intelligence (AI), providing an overview of a knee joint's clinical condition.
According to the company, Epioscopy is intended to assist healthcare professionals in their planning of optimal treatments for patients' knees by interactive 3D visualisation of structures and possible structural deviations.
Episurf Medical offers the Episealer personalised implants and Epiguide surgical drill guides, which are developed for treating localised cartilage injury in joints. Episurf Medical's µiFidelity system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business